The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

Scientific Webinar - The Importance of Early Optimized Treatment to Early Recovery of Daily Functioning

In this webinar, we will focus on achieving full functional recovery in patients with MDD including the improvement in cognitive, social and work functioning with case demonstration. The common symptoms of MDD, such as emotional blunting and anhedonia, and their implications for functional recovery will be analyzed. Dr. Wong will also share his expert opinion in the importance of individualized treatment in relation to the patients with various symptom profiles. The treatment options and holistic management of the patients with MDD will be reviewed in the lecture.

Joint Scientific Webinar - Recent Advances in The Management of Disorder of Gut-Brain Interaction – Part I

Disorders of Gut-Brain Interactions (DGBI) has been increasingly used to replace Functional Gastrointestinal Disorders (FGID) in recent years. The new terminology highlights the role of dysfunctional brain-gut axis in the pathophysiology of FGID. It is well known that most DGBI patients do not respond well to gut-directed therapy alone. An effective management approach of DGBI needs to be multi-targeted, which starts with evaluation of multidimensional clinical profile during diagnosis, stressor identification, lifestyle and dietary modification, and medical therapy. Owing to the high prevalence and strong association with psychiatric comorbidity, vigilance should be exercised to facilitate early intervention by mental health professionals. In recent years, gut microbial modulation through probiotics and functional food has been investigated for treatment of DGBI with promising results.

Scientific Webinar - Recent Advances in The Management of Major Depressive Disorder

This webinar will include a review of the advances in the management of MDD, with reference to the latest Canadian Network for Mood and Anxiety treatment clinical guidelines. Dr. Yip will also share three cases related to the use of antidepressants and the use of augmentation medications.

Joint Scientific Webinar Crosstalk Between The GI Tract and The Brain

Functional gastrointestinal disorders, also known as disorders of gut-brain interaction, is common among the adult population in Hong Kong. In this joint symposium, Prof. Justin Wu gives an overview on the bidirectional interaction between brain and gut, etiology, and treatment for these disorders. Prof. Tang Siu Wa discusses the role of inflammation in neuropsychiatric disorders with a perspective from traditional Chinese medicine.

COVID-19 & MDD: Current challenges and implications for clinical practice

In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.

The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

COVID-19 & MDD: Current challenges and implications for clinical practice

In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.

The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

COVID-19 & MDD: Current challenges and implications for clinical practice

In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.

Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder

Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.

The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

COVID-19 & MDD: Current challenges and implications for clinical practice

In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.

The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

COVID-19 & MDD: Current challenges and implications for clinical practice

In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.

Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder

Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.

Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?

The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.

The Psychiatric Emergency: Managing Agitated Patients

Agitation is one of the most common psychiatric emergencies seen in patients suffering from mental illnesses. The anxiety and isolation caused by the pandemic may also trigger this behavior. This webinar will focus on the different approaches in effectively managing agitated patients based on behavior severity. Relevant clinical guidelines on the topic will also be discussed.

The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

Tailoring Treatment for Depression: A focus on patients with Anhedonia or Emotional Blunting

In this session, the discussion will be focusing on the differences and similarities between anhedonia and emotional blunting, their impact on patients’ lives and how to identify them in clinical practice. New data will be shared on the effects of vortioxetine on anhedonia as well as from the COMPLETE study which focused on emotional blunting. The clinical implications of these studies and real-world observations will also be discussed.

COVID-19 & MDD: Current challenges and implications for clinical practice

In the first episode of the series, we will focus on the impact of COVID-19 on patients with MDD; we will explore the common MDD symptoms reported during the global pandemic as well as the current challenges and long-term implications this will present for clinical practice. This episode will also address treatment options and considerations, including vortioxetine*, for patients with MDD during and post-pandemic. Professor Roger McIntyre, alongside Dr Mohammad Alsuwaidan and Dr Nina Scheweinfurth, will present recently published clinical data and share their own clinical experiences of managing MDD during the pandemic. *Vortioxetine – is indicated for the treatment of major depressive episodes in adults. For local prescribing information, please refer to the information you have received from your local Lundbeck representative for this event.

Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder

Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.

Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?

The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.

The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder

Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.

Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?

The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.

The Great Debate: Treatment Strategies in The Management of MDD

Let's Rethink Cognition in Depression: What Does Improvement Mean To Our Patients?

COVID-19: Psychiatry Practices in The New Era

Managing Challenging Cases: Anxiety Disorders with Comorbidities

Masterclass Webinar Series - Antidepressant Treatment in Major Depressive Disorder

Childhood trauma is associated with negative neurobiological, physical, behavioural, psychosocial and mental health effects, and can increase the risk of early onset, relapse and chronicity of MDD (major depressive disorder). Resilience has been linked to better outcomes in MDD, including a decreased risk of onset and relapse. This webinar will explore the social, emotional, cognitive and biological systems implicated in resilience. Importantly, the role of resilience for MDD patients with history of childhood trauma will be discussed, as well as tips on fostering resilience in clinical practice.

Masterclass Webinar Series - Treatment Adjustment in MDD - What does success look like?

The majority of MDD (major depressive disorder) patients do not respond adequately to treatment, and a proper pharmacological management plan is key to ensuring full recovery. Switching, dose titration or augmentation of the current antidepressant are various options the clinician can undertake, and this webinar will include a debate on these options for maximal chance of recovery in MDD patients. In addition, the speakers will delve into the current treatment landscape of MDD, as well as the management of partial responders in MDD.

The art of disclosing depression to your patients - Focus on depression in younger adults

Do you struggle with disclosing mental disorders such as major depressive disorder (MDD) to your patients? How much do bedside manners really matter to the treatment plan? This session will discuss the trending topic of establishing the patient-doctor alliance and effective communication. In addition, the changing landscape of the treatment goal and management of MDD will be discussed, as well as practical advice via case studies of MDD management in active adults.